G1 is developing new oncology therapies that are currently in clinical trials
The Company is advancing its lead clinical compound trilaciclib, a first-in-class therapy designed to improve outcomes for patients who are treated with chemotherapy, in clinical trials assessing myeloprotection and anti-tumor efficacy endpoints in a variety of tumors types. To learn more about our clinical trials, please visit www.clinicaltrials.gov or contact us at firstname.lastname@example.org.
Patients and families should speak to their physician about risks and benefits of a clinical trial and to ask whether a study is right for them.
Trilaciclib is a first-in-class therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. Trilaciclib is currently being studied in colorectal cancer (“CRC”), metastatic triple negative breast cancer (“mTNBC”), neoadjuvant breast cancer, non-small cell lung cancer (“NSCLC”) and bladder cancer.
Rintodestrant is an oral selective estrogen receptor degrader (“SERD”) for the treatment of estrogen receptor-positive (“ER+”) breast cancer. The Company is in the process of evaluating partnering options for rintodestrant.
Lerociclib is a differentiated oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in types of breast and lung cancer. It is currently being studied in estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer and epidermal growth factor receptor mutation (EGFRm) non-small cell lung cancer. At this time, we have completed enrollment and are not recruiting patients for our ongoing trials.
We entered into separate, exclusive agreements with EQRx (rights for U.S., Europe, Japan, and all markets outside Asia-Pacific) and Genor (rights for Asia-Pacific, excluding Japan) for the development and commercialization of lerociclib in all indications.